| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/02/2002 | WO2001018172A3 Fibroblast growth factor-like polypeptides |
| 05/02/2002 | WO2001009121A3 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 05/02/2002 | WO2001002423A9 2'-guanidinyl-substituted oligonucleotides and gene expression modulation therewith |
| 05/02/2002 | WO2001000874A3 Cancer associated antigens and uses therefor |
| 05/02/2002 | WO2000061124A3 Use off cell membrane penetrating indigoid bisindole derivatives |
| 05/02/2002 | US20020052594 Method and kit for imaging and treating organs and tissues |
| 05/02/2002 | US20020052518 Taxane with a hydrocarbon having at the alpha position a group such as halogen at the 2' and/or 7 positions; enhanced in vivo hydrolysis for enhanced taxane therapeutic activity |
| 05/02/2002 | US20020052513 Oxamide IMPDH inhibitors |
| 05/02/2002 | US20020052477 Fibroblast growth factor homologous factor-1 (fhf-1) and methods of use |
| 05/02/2002 | US20020052471 Human procalcitonin and the preparation and use thereof |
| 05/02/2002 | US20020052443 Non-antigenic branched polymer conjugates |
| 05/02/2002 | US20020052404 Compositions and methods for treating or preventing diseases of body passageways |
| 05/02/2002 | US20020052403 Taxane formulations |
| 05/02/2002 | US20020052400 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. |
| 05/02/2002 | US20020052398 Pharmaceutical composition of 6-amino EM-12 |
| 05/02/2002 | US20020052397 Treatment of diseases characterized by excess Th2 cytokines and/ or an excess IgE production. |
| 05/02/2002 | US20020052393 Benzanilides as potassium channel openers |
| 05/02/2002 | US20020052386 Pyrimidine derivatives |
| 05/02/2002 | US20020052378 Novel compounds and compositions as protease inhibitors |
| 05/02/2002 | US20020052376 Imidazole derivatives and their use as farnesyl protein transferase inhibitors |
| 05/02/2002 | US20020052369 Indolinone derivatives as protein kinase/phosphatase inhibitors |
| 05/02/2002 | US20020052366 Administering taurolidine, taurultam, or a biologically active derivative; induces tumor cell death by apoptosis. |
| 05/02/2002 | US20020052352 Treating a malignant tumor, like a melanoma, using plant-derived compounds |
| 05/02/2002 | US20020052350 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses |
| 05/02/2002 | US20020052347 Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates |
| 05/02/2002 | US20020052346 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| 05/02/2002 | US20020052344 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB) |
| 05/02/2002 | US20020052343 Salicylamides as serine protease inhibitors |
| 05/02/2002 | US20020052334 Antisense oligonucleotide, a ribozyme, a protein, a polypeptide, an antibody, or a small molecule. |
| 05/02/2002 | US20020052333 Therapeutic use of cis-element decoys in vivo |
| 05/02/2002 | US20020052320 Sustained peptide-release formulation |
| 05/02/2002 | US20020052317 Anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
| 05/02/2002 | US20020052316 Bax-mediated apoptosis modulating reagents and methods |
| 05/02/2002 | US20020052315 Conformationally constrained backbone cyclized somatostatin analogs |
| 05/02/2002 | US20020052311 Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| 05/02/2002 | US20020052038 Polypeptide for use in the treatment of viral diseases and cancer |
| 05/02/2002 | US20020052035 18891, a novel human lipase |
| 05/02/2002 | US20020052028 Bio-intermediates for use in the chemical synthesis of polyketides |
| 05/02/2002 | US20020052013 Tumour-specific P450 protein |
| 05/02/2002 | US20020051984 Nucleotide sequences coding cell proliferation protein; for use in the treatment of cancer, wounds, inflammation, arthritis, psoraisis, vision and cell proliferation defects |
| 05/02/2002 | US20020051822 Enhancing bone formation, inhibiting osteoclastic differentiation or activating osteoblastic differentialation by administering to a human or animal suffering from, or susceptible to bone disease a lanthanum compound |
| 05/02/2002 | US20020051784 Methods for modulating T cell unresponsiveness |
| 05/02/2002 | US20020051780 Bind at the same time to the T-cell receptor complex, to tumour- associated antigens on a tumour cell, and, via the Fc portion of the bispecific antibody |
| 05/02/2002 | US20020051778 Method for treatment of malignant neoplasms and a complex preparation having antimalignant activity |
| 05/02/2002 | US20020051776 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 05/02/2002 | US20020051775 Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) |
| 05/02/2002 | US20020051774 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 05/02/2002 | US20020051773 Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) |
| 05/02/2002 | US20020051772 Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) |
| 05/02/2002 | US20020051765 Method of cancer treatment |
| 05/02/2002 | US20020051763 Recombinant viral genome and nucleic acid sequence, carried by one or two plasmid supports, transcomplementing each other and allowing the host cell to produce defective infectious viruses |
| 05/02/2002 | US20020051749 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma |
| 05/02/2002 | EP1202065A1 Net, a transcription factor of the TCF family, as regulator of angiogenic expression. |
| 05/02/2002 | EP1201680A2 Tumor suppressor polypeptide issued from CHC1-L (chromosome condensation 1-like) |
| 05/02/2002 | EP1201676A2 PNA-DNA-PNA chimeric macromolecules |
| 05/02/2002 | EP1201668A1 Staurosporin derivatives |
| 05/02/2002 | EP1201639A2 Lipoxin compounds and their use in treating cell proliferative disorders |
| 05/02/2002 | EP1201247A2 Treatment of tumor metastases and cancer |
| 05/02/2002 | EP1201237A1 Composition comprising an amide or a dialkylsulphoxide derivative for the treatment of cancer |
| 05/02/2002 | EP1201234A2 Treatment of diseases with adamantane derivates |
| 05/02/2002 | EP1201137A1 Cysteine/glycine rich peptides |
| 05/02/2002 | EP1200831A1 Modulating binding site on potassium channels used for screening |
| 05/02/2002 | EP1200623A2 Diagnostic method comprising wt1 sequences |
| 05/02/2002 | EP1200616A2 Enhanced delivery via serpin enzyme complex receptor ligands |
| 05/02/2002 | EP1200608A2 Chimeric polypeptides of serum albumin and uses related thereto |
| 05/02/2002 | EP1200607A2 Tet repressor-based transcriptional regulatory proteins |
| 05/02/2002 | EP1200602A1 Dsp-11 dual-specificity map kinase phophatase |
| 05/02/2002 | EP1200596A2 Human synthetases |
| 05/02/2002 | EP1200595A2 Myxoma virus genes for immune modulation |
| 05/02/2002 | EP1200594A2 Protective antigen of epstein barr virus |
| 05/02/2002 | EP1200590A1 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 05/02/2002 | EP1200587A2 Receptors and associated proteins |
| 05/02/2002 | EP1200586A2 Human nervous system-associated proteins |
| 05/02/2002 | EP1200585A1 T-cell receptor gamma alternate reading frame protein, (tarp) and uses thereof |
| 05/02/2002 | EP1200582A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 05/02/2002 | EP1200581A1 Truncated egf receptor |
| 05/02/2002 | EP1200579A2 Antisense therapy for hormone-regulated tumors |
| 05/02/2002 | EP1200573A1 Antisense modulation of mekk1 expression |
| 05/02/2002 | EP1200569A1 A method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 05/02/2002 | EP1200560A1 Melanin-concentrating hormone receptor |
| 05/02/2002 | EP1200479A1 Multiple cytokine-antibody complexes |
| 05/02/2002 | EP1200477A1 Prognosis and therapy of malignant diseases by antibodies which bind phosphorylated met protein |
| 05/02/2002 | EP1200476A1 Antitumor antibodies, proteins, and uses thereof |
| 05/02/2002 | EP1200461A2 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 05/02/2002 | EP1200459A1 Compounds for treatment of infectious and immune system disorders and methods for their use |
| 05/02/2002 | EP1200458A1 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (app) |
| 05/02/2002 | EP1200457A2 Cysteine protease inhibitors |
| 05/02/2002 | EP1200455A1 Enzyme catalyzed therapeutic activation |
| 05/02/2002 | EP1200454A1 Bisplatinum complexes active through the oral route |
| 05/02/2002 | EP1200451A1 Radiolabelled bisphosphonates and method |
| 05/02/2002 | EP1200444A1 Novel xanthone compounds, their preparation and use as medicament |
| 05/02/2002 | EP1200443A1 Aromatic esters of camptothecins and methods to treat cancers |
| 05/02/2002 | EP1200439A1 1,2-dihydro-1-oxo-parazino(1,2-a) indole derivatives |
| 05/02/2002 | EP1200434A1 NEW CYTOTOXIC PYRIDO 2,3,4-kl]ACRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| 05/02/2002 | EP1200430A1 Thiourea and isothiourea derivatives for inhibiting ras-transformed cell growth |
| 05/02/2002 | EP1200424A1 C7 heterosubstituted acetate taxanes as antitumor agents |
| 05/02/2002 | EP1200422A2 Pyrazole compositions useful as inhibitors of erk |
| 05/02/2002 | EP1200419A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 05/02/2002 | EP1200412A2 Imidazole antiproliferative agents |
| 05/02/2002 | EP1200399A1 Vitamin d3 analogs |